Semaglutide, tirzepatide and retatrutide are three incretin-related peptide analogues that are frequently compared because they sit along a progression from single- to multi-receptor activity. The single most important difference for a researcher is which receptors each compound engages. This guide compares their receptor profiles, structure, and development status, and clarifies how the reference compounds sold on ChainPep relate to the widely discussed prescription medicines. Everything here is for in-vitro research planning; it is not medical advice or an efficacy comparison.
Important distinction. Semaglutide and tirzepatide exist as approved prescription medicines under brand names; retatrutide has been in clinical development. ChainPep supplies lyophilized reference compounds for qualified laboratory research only — not these medicines, and not for human use.
Receptor profile at a glance
| Compound | Receptor activity | Pathway characterization |
|---|---|---|
| Semaglutide | GLP-1 | Long-acting single incretin agonist |
| Tirzepatide | GIP + GLP-1 | Dual incretin agonist |
| Retatrutide | GIP + GLP-1 + glucagon | Triple agonist |
Semaglutide (GLP-1)
Semaglutide is a long-acting analogue of glucagon-like peptide-1 (GLP-1) that activates the GLP-1 receptor. It is the most established of the three and is widely prescribed in regulated markets. In a research context, it serves as a reference for a single-receptor incretin arm, useful when the experimental question is specifically about GLP-1 signalling without contribution from GIP or glucagon.
Tirzepatide (GIP / GLP-1)
Tirzepatide adds activity at the glucose-dependent insulinotropic polypeptide (GIP) receptor to GLP-1, making it a dual incretin agonist. Including GIP activity is the key distinction from semaglutide. Research programs that want to compare a single- versus dual-incretin mechanism often run semaglutide and tirzepatide as separate arms. ChainPep supplies tirzepatide reference material for these in-vitro comparisons.
Retatrutide (GIP / GLP-1 / glucagon)
Retatrutide extends the pattern to a third receptor, adding glucagon receptor agonism to GIP and GLP-1. Glucagon-related signalling is the element absent from the other two. It is the reference compound of choice when the study question explicitly involves the glucagon pathway alongside the two incretin receptors. See the retatrutide product page for current specifications and the dedicated retatrutide research overview.
What the evidence does and does not establish
- These analogues differ in a clear, defensible way: the number and identity of their target receptors.
- Prescription semaglutide and tirzepatide have extensive clinical and regulatory records; retatrutide has progressed through clinical development. These records concern the medicines, not research-vial supply.
- Animal-model and in-vitro findings should not be presented as confirmed human outcomes, and no rank ordering of "strength" or weight-loss effect should be inferred from receptor count alone.
Choosing for a research program
- Define the receptor pathway the experiment is testing.
- Match the compound to the pathway: GLP-1 → semaglutide; GIP+GLP-1 → tirzepatide; GIP+GLP-1+glucagon → retatrutide.
- Verify each lot's identity and purity against its HPLC and ESI-MS records before use (see how to read a peptide COA).
- Confirm handling and storage with the reconstitution guide.
All three compounds are available in the Weight Loss research compounds category as documented lyophilized reference material, with lot records accessible from each product page.